It remains unknown whether microRNA (miRNA/miR) can target transfer RNA (tRNA) molecules. Here we provide evidence that miR-34a physically interacts with and functionally targets tRNA i Met precursors in both in vitro pulldown and Argonaute 2 (AGO2) cleavage assays. We find that miR-34a suppresses breast carcinogenesis, at least in part by lowering the levels of tRNA i
Met through AGO2-mediated repression, consequently inhibiting the proliferation of breast cancer cells and inducing cell cycle arrest and apoptosis. Moreover, miR-34a expression is negatively correlated with tRNA i
Met levels in cancer cell lines. Furthermore, we find that tRNA i
Met knockdown also reduces cell proliferation while inducing cell cycle arrest and apoptosis. Conversely, ectopic expression of tRNA i
Met promotes cell proliferation, inhibits apoptosis, and accelerates the S/G2 transition. Moreover, the enforced expression of modified tRNA i Met completely restores the phenotypic changes induced by miR-34a. Our results demonstrate that miR-34a directly targets tRNA i Met precursors via AGO2-mediated cleavage, and that tRNA i
Met functions as an oncogene, potentially representing a target molecule for therapeutic intervention.
miR-34a | tRNA i
Met | proliferation | cell cycle | apoptosis I n humans, the most well-defined tumor suppressor micro RNAs (miRNAs) are members of the miR-34 family, including miR-34a, miR-34b, and miR-34c. These miRNAs are encoded by two different genes; miR-34a is encoded by its own transcript, whereas miR-34b and miR-34c share a common primary transcript (1) . The loci harboring these two genes are located in regions associated with fragile sites of the genome that have been shown to be frequently altered in cancer (2) . Interestingly, recent findings suggest that members of the miR-34 family are direct transcriptional targets of the tumor suppressor p53 (3) (4) (5) (6) (7) , which is essential for miR-34 expression induced by DNA damage and oncogenic stress. Therefore, miR-34a may be a key player in the p53 network, mediating the biological function of p53 by regulating the expression of various genes. The inactivation of miR34a attenuates p53-mediated apoptosis in response to genotoxic stress (6) , whereas the ectopic expression of miR-34a causes a dramatic reprogramming of gene expression and induces cell cycle arrest, apoptosis, and senescence (3) (4) (5) (6) (7) .
The down-regulation or loss of miR-34a expression has been linked to the development of numerous types of cancer, including glioblastomas and malignant peripheral nerve sheath tumors as well as breast, colon, ovarian, pancreatic, and prostate cancers (3, (8) (9) (10) (11) (12) (13) . Both genetic and epigenetic mechanisms contribute to the reduction of miR-34a expression in malignant cells, including the inactivation of p53 and CpG methylation of the miR-34a promoter (11, 14) . miR-34a has been shown to directly target the 3′ UTRs of numerous oncogene mRNAs, including Bcl-2, SIRT1, Fra-1, E2F, c-Met, Notch1, Notch2, CDK4/6, VEGF, ARAF, PIK3R2, cyclin D3, cyclin E2, and PLK1 (4, 7, 9, 10, 13, 15, 16) , which may contribute to its tumor-suppressive role. However, whether miR-34a or other miRNAs can target tRNA molecules remains unknown.
Results

miR-34a Functionally Targets tRNA i
Met . We recently demonstrated that ionizing radiation induces miR-34a expression in human mammary epithelial cells (HMECs) (17) . At the same time, miR34a has been reported to be down-regulated in breast cancer samples (9) . Since overexpression of tRNAs has been demonstrated in breast cancer (18) , we analyzed the sequences of miR34a and mature tRNA molecules and realized that tRNA i Met could be a potential target of miR-34a. Sequence analysis revealed that the mature miR-34a and tRNA i
Met sequences in humans, rats, and mice share 100% identity, and a potential binding motif for miR-34a and tRNA i Met has been identified ( Fig. 1 A and B) . The predicted minimum free energy of the interaction between miR-34a and tRNA i
Met was −15.9 kcal/mol (Fig. 1B) , whereas the minimum free energy of disruption of the tRNA i Met acceptor arm was −15.2 kcal/mol.
We then studied the interaction of miR-34a with tRNA i Met molecules and precursors in cell-free extracts using various pulldown assays. Biotinylated Homo sapiens miR-34a (hsa-miR34a) was used as a probe to pull down its binding partners in vitro, and quantitative real-time RT-PCR (qRT-PCR) was used to quantify the tRNA i Met species captured by the miR-34a probe. The amount of captured tRNA i
Met species was increased in a dose-dependent fashion. Up to 2.5% of the total cellular tRNA i
Met could be captured from the cell-free extracts, while a nonspecific control probe showed no dose-dependent capture of tRNA i Met (Fig. 1C) tRNA i Met (pri-tRNA i Met ); however, in vitro experiments with pure species showed that unmodified tRNA i Met was amplified 30-fold more efficiently than the mature modified species (SI Appendix, Fig. S1 ).
To see whether immature tRNA i Met species could actually be captured from whole-cell lysates, we designed primers to amplify selectively any immature tRNA i Met species captured by the hsamiR-34a pulldown. Analysis showed that immature tRNA i G, 7-methylguanosine; mActin, mouse actin; mGAPDH, mouse GAPDH; MT-AGO, mutant AGO2 (D597N); NC siRNA, negative control siRNA; t 6 A, N6-threonylcarbamoyladenosine; tRF, tRNA i Met fragment; WT-AGO2, wild-type AGO2. *P < 0.05; **P < 0.03.
molecules (pretRNA i Met and/or pri-tRNA i Met ) were also enriched by the wild-type miR-34a probe (Fig. 1D) , although the efficiency of the pulldown of the longer species was only approximately onequarter of that seen with shorter amplicons. Taken together, these findings appear to show that miR-34a can target precursors of tRNA i
Met , but whether mature species are also targeted is not clear. miRNAs regulate gene expression through translational inhibition or transcript degradation via Argonaute 2 (AGO2)-catalyzed cleavage (19) . To determine if AGO2 is capable of miR-34a-directed tRNA i
Met cleavage, we stably transfected HCC1806 cells with a doxycycline (Dox)-inducible hsa-miR-34a plasmid (SI Appendix, Fig. S2 ). AGO2 was then precipitated from whole-cell lysates by a ChIP-grade antibody. Real-time RIP-PCR indicated that hsa-miR-34a was significantly enriched by anti-AGO2 antibodies (2.6-fold; P = 0.043) (Fig. 1E, Upper) , as expected. Immature tRNA i
Met was also significantly enriched (3.5-fold; P = 0.015) (Fig. 1E, Lower) . To test the AGO2-mediated tRNA i
Met cleavage hypothesis directly, we performed an in vitro cleavage assay (Fig. 1F) by incubating human AGO2 protein with miR-34a and either synthetic unmodified tRNA i
Met or a synthetic modified tRNA i Met that contained three of the posttranscriptional modifications present in mature tRNA i
Met or a synthetic scrambled version of the tRNA i Met sequence (Fig. 1G ). This assay showed that wild-type AGO2 could catalyze miR-34a-mediated cleavage of unmodified tRNA i
Met , but not the modified tRNA (20) . To test our hypothesis in vivo, this model was then validated by RNA-Seq analysis using enforced miR-34a expression HCC1806 cell line. We also note that the unmodified tRNA i Met sample that we used displays two bands in the gel (lanes 2-4, Fig. 1F , Left), and only the top, more intense one appeared to be cleaved by AGO2 (lane 4, Fig. 1F , Left). Mass spectrometry of the sample (Dharmacon), suggested that the top, more intense band is the bona fide unmodified tRNA i Met , while the lower, less intense band is a degradation product (SI Appendix, Fig. S3 ).
Interestingly, miR-34a did not target modified tRNA i Met (Fig.  1F, Left) . AGO2 cleavage of the miR-34a/tRNA i Met complex in vitro occurs efficiently with unmodified tRNA i Met , presumably due to the lack of modified ribonucleotides. This suggests that in vivo, miR-34a modulates the pool of mature functional tRNA i
Met primarily by depleting its precursors. Additional controls showed that miR-34a alone could not directly cleave tRNA i Met in either RNA-RNA binding buffer or DNAzyme cleavage buffer (21, 22) ; such cleavage occurred only when AGO2 was present in the AGO2-specific buffer (SI Appendix, Fig. S4 ).
To further confirm the key role of AGO2 in miR-34a-guided tRNA i
Met degradation, we then used mouse embryonic fibroblast NIH 3T3 AGO2 +/+ and AGO2 −/− lines as a model system to explore the effect of AGO2 on the expression of immature tRNA i Met . We found that a marked reduction of AGO2 led to a modest down-regulation of mm-miR-34a and profound overexpression of immature tRNA i Met (Fig. 1H) . In contrast, restored expression of AGO2 in NIH 3T3 AGO2
−/− cells resulted in a modest up-regulation of mm-miR-34a and a remarkable reduction of the immature tRNA i Met (Fig. 1I) . (Fig. 2A) . miR-34a was down-regulated in all of the breast cancer cell lines examined (Fig. 2B, Upper) , consistent with recent reports (9, 13). Interestingly, the levels of immature tRNA i Met were elevated in these breast cancer cell lines (Fig. 2B, Lower) and were generally inversely correlated with the levels of miR-34a (Fig. 2B, Upper) , suggesting that miR-34a may be a significant regulator of tRNA i
Met level. To establish the ratio of endogenous miR-34a to tRNA i
Met molecules, we generated standard curves with two variants of Ct value and molecule number (SI Appendix, Fig. S5  A and B) , and then calculated and analyzed the numbers of both molecules in IR-exposed HMECs and breast cancer cell lines (SI Appendix, Fig. S6 A and B) . The ratio of miR-34a to total tRNA i Met molecules ranged from 1:17 to 1:19 in IR-exposed HMECs, but from 1:7.3 × 10 3 to 1:1.7 × 10 5 in breast cancer cell lines. We found that total tRNA i Met was also down-regulated in the IR-exposed HMECs and overexpressed in all breast cancer cell lines examined (SI Appendix, Fig. S7 A and B) .
miR-34a Suppresses Cell Proliferation and Induces Cell Cycle Arrest and Apoptosis. miR-34a has been suggested to play an important role in cancer cell proliferation, apoptosis, migration, and invasion (3, (8) (9) (10) (11) (12) (13) . Thus, we further examined the significance of miR-34a in breast carcinogenesis using the Dox-inducible miR34a-expressing HCC1806 cell line as a model system. We found that miR-34a induced by Dox significantly suppressed breast cancer cell proliferation (Fig. 3 A and B) . 
S8A
) and substantially induced S-phase cell cycle arrest and apoptosis in the HCC1806 cells ( Fig. 3 C and D) . We also noted that the copy number of miR-34a is higher in HCC1806 cells expressing miR-34a [1.5-fold higher for Dox(−) and twofold higher for Dox(+)] compared with the parental cells (SI Appendix, Fig. S8B ). Furthermore, application of 800 ng/mL doxycycline (the same dose used for inducible miR-34a expression in HCC1806 cells expressing miR-34a) had no effect on HCC1806 cell proliferation (SI Appendix, Fig. S8C ), although a transient reduction in the expression of total tRNA i Met was found at 24 h after treatment (SI Appendix, Fig. S8D ).
To further validate our findings, we evaluated the effect of ectopic miR-34a expression on apoptosis and cell cycle in another breast cancer cell line, MCF7. Flow cytometry analyses showed a modest but significant induction of apoptosis and G2 arrest in MCF7 cells transfected with miR-34a (SI Appendix, Fig. S9 A-C) .
Knockdown of tRNA i Met Attenuates Cell Proliferation and Induces
Apoptosis and G1-Phase Arrest. We next generated a stable tRNA i
Met -knockdown HCC1806 cell line to explore the role of tRNA i
Met in breast cancer and to establish whether the biological effects of miR-34a are mediated, at least in part, by the targeting of tRNA i Met . As expected, knockdown of tRNA i Met attenuated cell proliferation (Fig. 4 A and B) and induced apoptosis and G1-phase cell cycle arrest (Fig. 4 C and D) . Fig. S10D ). These results indicate the specificity of wild-type tRNA i Met dsiRNA function. We stably transfected MCF7 cells with the same shRNA vectors and found similar reductions in cell proliferation (SI Appendix, Fig. S11 A and B) , induction of G1 arrest (SI Appendix, Fig. S11C ), and induction of apoptosis (SI Appendix, Fig. S11D ). Met . As expected, miR-34a-induced suppression of proliferation and induction of apoptosis ( Fig. 5 A and C) were completely restored by transfection with modified tRNA i Met (Fig. 5 D and F) .
Discussion
Although thousands of miRNA targets have been discovered to date, no evidence that miRNAs can target tRNA molecules has been reported. This study reveals that the tumor suppressor miR-34a can directly target unmodified tRNA i Met , leading to tRNA i Met degradation via AGO2-mediated cleavage, and suggests a conceptually and mechanistically novel process in miRNAmediated posttranscriptional regulation. We demonstrate a physical and functional interaction between these two molecules in in vitro pulldown and AGO2 cleavage assays. We also provide evidence that tRNA i Met may act as an oncogene. As a key player in miRNA-mediated mRNA degradation, AGO2 may also play a pivotal role in miR-34a-directed tRNA i Met cleavage, since miR-34a failed to cleave unmodified tRNA i Met in the presence of mutant AGO2 and occurred only in the presence of wild-type AGO2. Although we show that miR-34a selectively targets unmodified tRNA i Met , most likely in the nucleus, we cannot exclude the possibility that miR-34a could also somehow target fully mature tRNA i Met in the cytoplasm, since the modified tRNA i
Met used in our experiments was not fully modified due to technical restrictions. Even though we have proposed a model to display the possible cleavage sites based on the data from in vitro AGO2 cleavage assay and RNA-Seq analysis, it may not fully represent the in vivo situation. Although the role of AGO2 in miR34a-induced tRNA i Met degradation has not been reported previously, AGO2 has been shown to bind selectively to tRNA Met in human HEK293 cells (23) . Sequence analysis predicts that miR34a may also target other tRNAs in addition to tRNA i Met , such as tRNA Leu(CAG) , tRNA Glu(TTC) , and tRNA Arg(CCT) . The existence and potential biological repercussions of these interactions require future study.
Our findings are strengthened because the sequences of mature tRNA i
Met are mostly identical among humans, rats, and mice, including the 3′ terminal sequence that we believe to be involved in binding to miR-34a (SI Appendix, Table S1 ). The canonical mechanism of miRNA-mediated mRNA cleavage requires perfect or nearly perfect complementarity, which is not the case for miR-34a:tRNA i Met pairs. However, the data we present here demonstrate that the binding motif between miR34a and tRNA i Met appears to be more stable than the tRNA i Met arm. Furthermore, there is strong evidence that in the case of miRNA-directed mRNA degradation in mammals, the complementarity between miRNA and mRNA is largely imperfect (24, 25) , although the mechanisms involved are unclear and require further investigation. The data presented here highlight that miR-34a could directly target unmodified immature tRNA i Met ( Fig. 1 D-F) . We are not sure whether miR-34a can interact in vivo with mature tRNA i Met .
One previously unsuspected role of tRNA i Met modifications may be to protect this tRNA against miR-34a-mediated AGO2 cleavage; since modified nucleotides m1G9 and m5C47 both locate at a structurally important junction of tRNA i Met , they may increase tRNA thermal stability, consequently preventing this tRNA from degradation (26) . Although it is unclear why miR-34a does not target cleavage of modified tRNA i Met , we suggest that tRNA i Met modifications may inhibit binding of miR-34a and AGO2 to tRNA. Even though our findings suggest a direct interaction between miR-34a and unmodified immature tRNA i Met , tRNA molecules are highly structured; their 3′ ends generally form a doublestranded structure with their 5′ ends in which it is termed the amino acyl arm. How the double-stranded structures are unwound to permit recognition by miR-34a remains unclear. In addition to Dicer, a core component of the RICS complex that mediates duplex unwinding (27) , conformational alterations of RICS during assembly may also contribute to unwinding the double-stranded structure (28) . Furthermore, a recent study has indicated an involvement of RNA helicase A in RNA duplex unwinding (29) . Here we show that an interaction between miR34a and highly structured tRNA i Met may be mediated via AGO2. To date, few studies have taken into consideration secondary structures of 3′ UTRs that interact with miRNAs. Among those, it was recently shown that miR-26b targets highly structured EphA2 mRNA (30, 31) , with this interaction mediated by a classical RISC complex. In the future, it would be interesting to conduct an in-depth analysis of all participating members of the RISC complex and any associated proteins.
For several years, deregulated protein synthesis has been associated with oncogenic transformation and tumorigenesis (32) . Indeed, cancer cells typically exhibit an increased growth rate, which may be due, at least in part, to the global up-regulation of tRNA molecules (33) . Although tRNA levels are elevated in human malignancies such as breast cancer (18) , the underlying mechanism remains poorly understood. Here we provide evidence that miR-34a plays an important role in governing the levels of tRNA i Met , and that this interaction may affect levels of cellular proliferation and apoptosis. Taken together, our findings may serve as an important roadmap for future analyses of interactions of miRNAs and other noncoding RNAs, their roles in regulation of key biological processes, and their contributions to carcinogenesis. 
